TABLE 3.

SIT and SBT over time for LCB01-0371 and linezolid against Gram-positive pathogens^a

Organism	Drug	Dose (mg)	Titer range		No. subjects with SIT of:		No. subjects with SBT of:
			SIT	SBT	≥2	≥4	≥2	≥4
S. aureus ATCC 29213	LCB01-0371	400	<2–4	<2	5	1	0	0
	LCB01-0371	800	2–4	<2–4	6	1	2	1
	Linezolid	600	<2–8	<2–4	5	5	2	2
E. faecalis ATCC 51299	LCB01-0371	400	<2–2	<2	5	0	0	0
	LCB01-0371	800	2–4	<2	6	1	0	0
	Linezolid	600	4–8	<2–8	6	6	4	4
MRSA ATCC 43300	LCB01-0371	400	<2–2	<2	1	0	0	0
	LCB01-0371	800	2–4	<2–2	6	1	1	0
	Linezolid	600	4–8	<2–8	6	6	3	3
S. pneumoniae ATCC 49619	LCB01-0371	400	<2	<2	0	0	0	0
	LCB01-0371	800	<2	<2	0	0	0	0
	Linezolid	600	<2	<2	0	0	0	0

^aSIT, serum inhibitory titer; SBT, serum bactericidal titer. Values are the SIT and SBT at the peak time point (1 h after dosing). Six subjects received each dose.